1. Home
  2. ESEA vs BLSM Comparison

ESEA vs BLSM Comparison

Compare ESEA & BLSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Euroseas Ltd. (Marshall Islands)

ESEA

Euroseas Ltd. (Marshall Islands)

N/A

Current Price

$64.25

Market Cap

557.0M

ML Signal

N/A

Logo BlossomHill Therapeutics Inc. Common Stock

BLSM

BlossomHill Therapeutics Inc. Common Stock

N/A

Current Price

$13.44

Market Cap

483.4M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ESEA
BLSM
Founded
2005
2020
Country
Greece
United States
Employees
N/A
N/A
Industry
Marine Transportation
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
557.0M
483.4M
IPO Year
2005
2026

Fundamental Metrics

Financial Performance
Metric
ESEA
BLSM
Price
$64.25
$13.44
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
5
Target Price
★ $91.75
$35.40
AVG Volume (30 Days)
22.3K
★ 131.5K
Earning Date
11-17-2026
11-19-2026
Dividend Yield
★ 5.06%
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.94
N/A
P/E Ratio
$3.39
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$51.00
$11.22
52 Week High
$79.67
$27.99

Technical Indicators

Market Signals
Indicator
ESEA
BLSM
Relative Strength Index (RSI) 32.99 42.76
Support Level $59.55 $12.93
Resistance Level $73.19 $17.53
Average True Range (ATR) 2.24 1.66
MACD -0.17 -0.06
Stochastic Oscillator 10.46 44.62

Price Performance

Historical Comparison
ESEA
BLSM

About ESEA Euroseas Ltd. (Marshall Islands)

Euroseas Ltd is a shipping company. Its fleet consists of containerships that transport container boxes, providing scheduled service between ports. Its operations are managed by an affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. The company employs its vessels on spot and period charters and through pool arrangements.

About BLSM BlossomHill Therapeutics Inc. Common Stock

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.

Share on Social Networks: